TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02896296
Drug: RBP-6000
Normalized name: COCAINE ESTERASE (RBP-8000)
DrugBank: COCAINE ESTERASE (RBP-8000) (DB19225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.
Study: NCT02066870
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
Study: NCT02066870
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved.
Study: NCT00637481
Drug: atorvastatin calcium
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT04077983
Drug: combined therapy using nab-paclitaxel and gemcitabine chemotherapy
Normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~2. Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~3. Three weeks is a course of treatment with a total of 4 courses.
Study: NCT03334084
Drug: ARGX-113
Normalized name: ARGX-119
DrugBank: ARGX-119 (DB18133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous or subcutaneous administration
Study: NCT02169752
Drug: Ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner.
Study: NCT02212392
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
Study: NCT03752294
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up.
Study: NCT02671058
Drug: Cortenema
Normalized name: Cortenema
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone Administered as a Liquid Enema
Study: NCT01299779
Drug: PEG-SD
Normalized name: Alphanine SD
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-SD~* Bisacodyl: two 5-mg tablets at 3 pm day prior~* 1L sports drink\* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior~* 1L SD\* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy~  * Same flavor, non-red Gatorade® for all patients.
Study: NCT01554111
Drug: Picosulfate sodium,
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One sachet of picosalax will be given with at least 4 cups of clear fluids.
Study: NCT01554111
Drug: Pico-Salax and Sodium phosphate enema
Normalized name: sodium phosphate, dibasic / sodium phosphate, monobasic Enema
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pt will take one sachet of Pico-salax the evening prior to procedure and fleet enema 1 hour before leaving home on the morning of the procedure
Study: NCT00702793
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
Study: NCT02468323
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
Study: NCT01044433
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT01547728
Drug: Recombinant antithrombin (rhAT)
Normalized name: ANTITHROMBIN III,RECOMBINANT
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
Study: NCT03893617
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single oral dose (80mg) of propranolol will be administered in a blinded capsule at the start of the baseline monitoring period of the acute stress study visit.
Study: NCT02468323
Drug: Palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping
Study: NCT01173536
Drug: GDC-0449
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral repeating dose
Study: NCT01173536
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral single dose
Study: NCT04007835
Drug: Anlotinib Hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of EGFR-TKIs
Study: NCT00156650
Drug: Acyline
Normalized name: Acyline
DrugBank: Acyline (DB11906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks
Study: NCT00156650
Drug: Depo-Medroxyprogesterone
Normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg IM every 3 months
Study: NCT00084097
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04397653
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the intervention arm evolocumab 140 mg subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Study: NCT01390051
Drug: Innohep (Tinzaparin)
Normalized name: tinzaparin sodium Injectable Solution [Innohep]
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 4,500 IU daily in half of the study populationrandomised to treatment
Study: NCT01390051
Drug: tinzaparin
Normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 4,500 IE daily
Study: NCT04397653
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe 10 mg daily will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia in both the placebo arm (plus placebo) and in the intervention arm (plus evolocumab)
Study: NCT00794794
Drug: Desloratadine (Clarinex)
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject received 5 mL of desloratadine syrup one time
Study: NCT00794794
Drug: Cetirizine (Zyrtec)
Normalized name: cetirizine Oral Solution [Zyrtec]
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject received 5 mL of cetirizine syrup
Study: NCT03481517
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 5 mL subcutaneous injection to surgical wound during operation.
Study: NCT00000380
Drug: GHRH
Normalized name: GHRH
DrugBank: Tesamorelin (DB08869)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03191305
Drug: Coumadin
Normalized name: Coumadin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day. The total duration Of coumadin would be six months.
Study: NCT03191305
Drug: Rivoroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.
Study: NCT04231292
Drug: RD01
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin
Study: NCT04231292
Drug: Recombinant Human Erythropoiesis Injection (CHO cell)
Normalized name: hyaluronidase, human recombinant Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
Study: NCT01979016
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00266487
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00266487
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03145285
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision.
Study: NCT00633022
Drug: LOSMAPIMOD 7.5 MG
DrugBank: Losmapimod (DB12270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.
Study: NCT01124422
Drug: fluticasone propionate/salmeterol inhalation powder DISKUS 250/50
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS
Study: NCT01124422
Drug: tiotropium bromide inhalation powder HandiHaler
Normalized name: tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label drug also known as Spiriva HandiHaler
Study: NCT01968031
Drug: Istradefylline 40 mg
Normalized name: istradefylline 40 MG
DrugBank: Istradefylline (DB11757)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Istradefylline 40 mg and placebo
Study: NCT01285089
Drug: activated recombinant human factor VII
Normalized name: Activated Recombinant Human Factor VII, Long Acting
DrugBank: Eptacog alfa pegol (activated) (DB11661)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data collection of the use of activated recombinant human factor VII observed through real-world treatment practices
Study: NCT03677401
Drug: 5mg Serlopitant Tablets
Normalized name: Serlopitant
DrugBank: Serlopitant (DB12973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serlopitant Tablets
Study: NCT01968031
Drug: Istradefylline 20 mg
Normalized name: istradefylline 20 MG
DrugBank: Istradefylline (DB11757)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Istradefylline 20 mg and placebo
Study: NCT00475410
Drug: ASCs (Cx401, company code)
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then.
Study: NCT00475410
Drug: Fibrin adhesive
Normalized name: thrombin
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
Study: NCT02130973
Drug: Experimental Cyclic Regimen
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Cyclic Regimen
Study: NCT00157534
Drug: Celgosivir
Normalized name: Celgosivir
DrugBank: Celgosivir (DB06580)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01095016
Drug: Meptin swinghaler
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dose: 10ug/puff, 2 puffs daily~* Frequency: QD (total 20ug/day)~* Treatment duration: 2 days
Study: NCT01095016
Drug: Berotec
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dose: 100ug/puff, 2 puffs daily~* Frequency: QD (total 200ug/day)~* Treatment duration: 2 days
Study: NCT00271583
Drug: levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01394133
Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
Study: NCT02301494
Drug: 3.75% Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
Study: NCT02301494
Drug: 0.1% Fluocinonide Cream
DrugBank: Fluocinonide (DB01047)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
Study: NCT04640194
Drug: Alteplase low dose
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.02 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.3 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
Study: NCT00797030
Drug: cyclosporine and sodium carboximethycellulose
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
Study: NCT00797030
Drug: sodium carboximethycellulose
Normalized name: Carboxymethylcellulose Sodium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
Study: NCT02013791
Drug: Cyclosporine New Ophthalmic Formulation
Normalized name: cyclosporine Ophthalmic Solution
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine New Ophthalmic Formulation administered as per protocol
Study: NCT03580694
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab will be administered by intravenous (IV) infusion.
Study: NCT01324999
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg/day for one month then 40mg/day for additional 4 months
Study: NCT00923247
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
Study: NCT00923247
Drug: Vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 \& 11 every 28 days in adults
Study: NCT04258397
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone vs. matching placebo
Study: NCT00302835
Drug: non-phenacetin containing analgesics
Normalized name: phenacetin
DrugBank: Phenacetin (DB03783)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02387060
Drug: H-Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
Study: NCT03748147
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prostaglandin e1
Study: NCT02012075
Drug: Extended-Release Carvedilol Sulfate
Normalized name: carvedilol Extended Release Oral Capsule
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02012075
Drug: Sustained-release Metoprolol Succinate
Normalized name: metoprolol Extended Release Oral Capsule
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01691781
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will receive one week of lisinopril and return for repeat for blood measurements.
Study: NCT00304993
Drug: fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00304993
Drug: niacin
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00304993
Drug: rosiglitazone
Normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01927224
Drug: Nifurtimox (BAYa2502) (4 x 30 mg tablet)
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
Study: NCT01927224
Drug: Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
Study: NCT04640194
Drug: Alteplase high dose
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.6 milligram/kilogram (mg/kg) over 2 hours (Day 1) immediately followed by daily infusion of 0.04 mg/kg/hour over 12 hours (starting on Day 1 and up to Day 5). One optional additional infusion of 0.6 mg/kg over 2 hours could be given once on Days 2 to 5 in case of clinical worsening, per investigator judgement.
Study: NCT02288923
Drug: Intra-operative medication
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)
Study: NCT02288923
Drug: Post-operative analgesia - morphine
Normalized name: Sx1 Medicated Post-Operative System KIT
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight \>70kg 2 hourly.
Study: NCT01927224
Drug: Nifurtimox (BAYa2502) (120 mg tablet)
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
Study: NCT00667069
Drug: triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00892762
Drug: Travoprost APS 40 micrograms/ml eye drop solution
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: non-BAK (benzalkonium chloride) medication
Study: NCT00892762
Drug: Latanoprost 50 micrograms/ml eye drop solution
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BAK-preserved medication
Study: NCT02420392
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
Study: NCT01895569
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin will be added to therapy for the first threre months.